Abstract:Depression is characterized by inflammation and cell-mediated immune (CMI) activation and autoimmune reactions directed against a multitude of self-epitopes. There is evidence that the inflammatory response in depression causes dysfunctions in the metabolism of 5-HT, e.g. lowering the 5-HT precursor tryptophan, and upregulating 5-HT receptor mRNA. This study has been undertaken to examine autoimmune activity directed against 5-HT in relation to CMI activation and inflammation.5-HT antibodies were examined in major depressed patients (n=109) versus normal controls (n=35) in relation to serum neopterin and lysozyme, and plasma pro-inflammatory cytokines (PIC), i.e. interleukin-1 (IL-1) and tumor necrosis factor-α (TNFα). Severity of depression was assessed with the Hamilton Depression Rating Scale (HDRS) and severity of fatigue and somatic symptoms with the Fibromyalgia and Chronic Fatigue Syndrome (FF) Rating Scale.The incidence of anti-5-HT antibody activity was significantly higher in depressed patients (54.1%), and in particular in those with melancholia (82.9%), than in controls (5.7%). Patients with positive 5-HT antibodies showed increased serum neopterin and lysozyme, and plasma TNFα and IL-1; higher scores on the HDRS and FF scales, and more somatic symptoms, including malaise and neurocognitive dysfunctions. There was a significant association between autoimmune activity to 5-HT and the number of previous depressive episodes.The autoimmune reactions directed against 5-HT might play a role in the pathophysiology of depression and the onset of severe depression. The strong association between autoimmune activity against 5-HT and inflammation/CMI activation is explained by multiple, reciprocal pathways between these factors. Exposure to previous depressive episodes increases the incidence of autoimmune activity directed against 5-HT, which in turn may increase the likelihood to develop new depressive episodes. These findings suggest that sensitization (kindling) and staging of depression are in part based on progressive autoimmune responses.

Evidence for an immune response in major depression: a review and hypothesis.

Evidence for an Immune Response in Major Depression: A Review and Hypothesis

Serotonin-Immune Interactions in Major Depression

Α Review on the Acute Phase Response in Major Depression

Evidence for a Systemic Immune Activation During Depression: Results of Leukocyte Enumeration by Flow Cytometry in Conjunction with Monoclonal Antibody Staining

Increased Serum IL-6 and IL-1 Receptor Antagonist Concentrations in Major Depression and Treatment Resistant Depression.

Increased Neopterin and Interferon-Gamma Secretion and Lower Availability of L-tryptophan in Major Depression: Further Evidence for an Immune Response

Major Depression and Activation of the Inflammatory Response System

Increased Plasma Concentrations of Interleukin-6, Soluble Interleukin-6, Soluble Interleukin-2 and Transferrin Receptor in Major Depression.

Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression.

Increased Serum Interleukin-1-receptor-antagonist Concentrations in Major Depression

Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression.

The acute phase response in depression: A review

Immunoendocrine Aspects of Major Depression

Major Depression: An Immune-Inflammatory Disorder

Indicators of Immune Activation in Major Depression.

Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut.

Activation of the Inflammatory Response System: A New Look at the Etiopathogenesis of Major Depression.

Immune Disturbances During Major Depression: Upregulated Expression of Interleukin-2 Receptors

Disturbances in Acute Phase Plasma Proteins During Melancholia: Additional Evidence for the Presence of an Inflammatory Process During That Illness

Immunological Differences Between Patients with Major Depression and Somatization Syndrome